Firms originating from these nations jointly control 19 out of 28 assets globally.
According to reports, South Korea and China are at the forefront of developing degrader-antibody conjugates (DACs), which represent a new category of targeted therapies in precision medicine.
GlobalData.
The development of DAC technology is still in its initial phases globally, with 28 projects currently underway. Among these initiatives, firms from South Korea and China together comprise 19 of the planned assets.
“Thanks to these innovative resources, South Korean and Chinese firms have the opportunity to draw in and broaden their strategic partnerships with international counterparts,” stated Nadim Anwer, a Pharma Analyst at GlobalData.
DACs are developed to address the drawbacks of conventional antibody-drug conjugates (ADCs) by merging the precision of antibodies with the strength of protein degraders.
“It is premature to assess the clinical success of this class; nonetheless, it is attracting interest as a novel field of study,” Anwer noted.
